Sheldon E. Litwin
YOU?
Author Swipe
View article: Epicardial adipose tissue, functional status, and invasive exercise hemodynamics in heart failure with preserved ejection fraction: Insights from the REDUCE LAP-HF II trial
Epicardial adipose tissue, functional status, and invasive exercise hemodynamics in heart failure with preserved ejection fraction: Insights from the REDUCE LAP-HF II trial Open
Background Obesity is strongly associated with the development of heart failure (HF) with preserved ejection fraction (HFpEF). Beyond increased body mass index (BMI), an abundance of epicardial adipose tissue (EAT) may play a role in its p…
View article: HFpEF-ABA score is a more useful enrichment tool than natriuretic peptides in heart failure with preserved ejection fraction
HFpEF-ABA score is a more useful enrichment tool than natriuretic peptides in heart failure with preserved ejection fraction Open
View article: Epicardial adipose tissue, functional status and invasive hemodynamics in heart failure with preserved ejection fraction.
Epicardial adipose tissue, functional status and invasive hemodynamics in heart failure with preserved ejection fraction. Open
EAT thickness was associated with impaired quality of life, lower 6-MWD and higher left-sided filling pressures at peak exercise. Excess EAT may therefore play an important role in functional status and exercise hemodynamics in patients wi…
View article: Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial
Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial Open
Background and Aims An expansion of fat mass is an integral feature of patients with heart failure and preserved ejection fraction (HFpEF). While body mass index (BMI) is the most common anthropometric measure, a measure of central adiposi…
View article: Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity
Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity Open
BACKGROUND: Patients with heart failure with preserved ejection fraction and obesity have significant disability and frequent exacerbations of heart failure. We hypothesized that tirzepatide, a long-acting agonist of glucose-dependent insu…
View article: Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial
Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial Open
Patients with obesity-related heart failure with preserved ejection fraction (HFpEF) display circulatory volume expansion and pressure overload contributing to cardiovascular–kidney end-organ damage. In the SUMMIT trial, patients with HFpE…
View article: Interatrial Shunt Treatment for Heart Failure: The Randomized RELIEVE-HF Trial
Interatrial Shunt Treatment for Heart Failure: The Randomized RELIEVE-HF Trial Open
BACKGROUND: An interatrial shunt may provide an autoregulatory mechanism to decrease left atrial pressure and improve heart failure (HF) symptoms and prognosis. METHODS: Patients with symptomatic HF with any left ventricular ejection fract…
View article: Long term safety and outcomes after atrial shunting for heart failure with preserved or mildly reduced ejection fraction: 5-year and 3-year follow-up in the REDUCE LAP-HF I and II trials
Long term safety and outcomes after atrial shunting for heart failure with preserved or mildly reduced ejection fraction: 5-year and 3-year follow-up in the REDUCE LAP-HF I and II trials Open
View article: Proposed Mechanisms and Associations of COVID-19 with Cardiometabolic Risk Factors
Proposed Mechanisms and Associations of COVID-19 with Cardiometabolic Risk Factors Open
Cardiovascular disease (CVD) and cardiometabolic risk (CMR) are highly prevalent globally. The interplay between CVD/CMR and COVID-19 morbidity and mortality has been intensely studied over the last three years and has yielded some importa…
View article: A novel controlled metabolic accelerator for the treatment of obesity‐related heart failure with preserved ejection fraction: Rationale and design of the Phase 2a <scp>HuMAIN</scp> trial
A novel controlled metabolic accelerator for the treatment of obesity‐related heart failure with preserved ejection fraction: Rationale and design of the Phase 2a <span>HuMAIN</span> trial Open
Aims Compared with those without obesity, patients with obesity‐related heart failure with preserved ejection fraction (HFpEF) have worse symptoms, haemodynamics, and outcomes. Current weight loss strategies (diet, drug, and surgical) work…
View article: Executive Summary from the 2023 Charleston HFpEF Conference
Executive Summary from the 2023 Charleston HFpEF Conference Open
View article: Atrial Shunt Device Effects on Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction
Atrial Shunt Device Effects on Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction Open
Importance Although the results of A Study to Evaluate the Corvia Medical Inc IASD System II to Reduce Elevated Left Atrial Pressure in Patients with Heart Failure (REDUCE LAP-HF II) trial were neutral overall, atrial shunt therapy demonst…
View article: Catheter Ablation of Atrial Fibrillation in Patients with Cor Triatriatum Sinister; A Case Series and Review of the Literature
Catheter Ablation of Atrial Fibrillation in Patients with Cor Triatriatum Sinister; A Case Series and Review of the Literature Open
Introduction: Cor triatriatum sinister (CTS) is a rare congenital heart defect associated with atrial fibrillation (AF). The incidence of hemodynamically insignificant CTS in the AF ablation population and its effect on ablation success ar…
View article: Obesity in heart failure with preserved ejection fraction: Insights from the <scp>REDUCE LAP‐HF II</scp> trial
Obesity in heart failure with preserved ejection fraction: Insights from the <span>REDUCE LAP‐HF II</span> trial Open
Aims Obesity is causally related to the development of heart failure with preserved ejection fraction (HFpEF) but complicates the diagnosis and treatment of this disorder. We aimed to determine the relationship between severity of obesity …
View article: Right Ventricular Function and Pulmonary Coupling in Patients With Heart Failure and Preserved Ejection Fraction
Right Ventricular Function and Pulmonary Coupling in Patients With Heart Failure and Preserved Ejection Fraction Open
View article: Exercise-Induced Left Atrial Hypertension in Heart Failure With Preserved Ejection Fraction
Exercise-Induced Left Atrial Hypertension in Heart Failure With Preserved Ejection Fraction Open
View article: Left atrial enlargement is associated with pulmonary vascular disease in heart failure with preserved ejection fraction
Left atrial enlargement is associated with pulmonary vascular disease in heart failure with preserved ejection fraction Open
Aims Elevated left atrial (LA) pressure is a pathophysiologic hallmark of heart failure with preserved ejection fraction (HFpEF). Chronically elevated LA pressure leads to LA enlargement, which may impair LA function and increase pulmonary…
View article: Assessing clinical and biomarker characteristics to optimize the benefits of sacubitril/valsartan in heart failure
Assessing clinical and biomarker characteristics to optimize the benefits of sacubitril/valsartan in heart failure Open
Of the various medical therapies for heart failure (HF), sacubitril/valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor that combines sacubitril, a pro-drug that is further metabolized to the neprilysin inhibitor sacubi…
View article: Update on Atrial Shunt Therapy for Treatment of Heart Failure
Update on Atrial Shunt Therapy for Treatment of Heart Failure Open
Heart failure with preserved ejection fraction is associated with elevated left atrial pressure during exercise. Sodium-glucose cotransporter-2 inhibitors have demonstrated the evidence of benefit in heart failure with preserved ejection f…
View article: Dapagliflozin for heart failure according to body mass index: the DELIVER trial
Dapagliflozin for heart failure according to body mass index: the DELIVER trial Open
Aims Obesity is common and associated with unique phenotypic features in heart failure with preserved ejection fraction (HFpEF). Therefore, understanding the efficacy and safety of new therapies in HFpEF patients with obesity is important.…
View article: Table of Contents
Table of Contents Open
View article: Endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction: early results of the <scp>REBALANCE‐HF</scp> trial roll‐in cohort
Endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction: early results of the <span>REBALANCE‐HF</span> trial roll‐in cohort Open
Aims In heart failure (HF) with preserved ejection fraction (HFpEF), excessive redistribution of blood volume into the central circulation leads to elevations of intracardiac pressures with exercise limitations. Splanchnic ablation for vol…
View article: Table of Contents
Table of Contents Open
View article: Resting and exercise haemodynamic characteristics of patients with advanced heart failure and preserved ejection fraction
Resting and exercise haemodynamic characteristics of patients with advanced heart failure and preserved ejection fraction Open
Aims This study aimed to describe haemodynamic features of patients with advanced heart failure with preserved ejection fraction (HFpEF) as defined by the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Methods…
View article: Ultrasound-Enhancing Agents and Associated Adverse Reactions: A Potential Connection to the COVID-19 Vaccines?
Ultrasound-Enhancing Agents and Associated Adverse Reactions: A Potential Connection to the COVID-19 Vaccines? Open
View article: Splanchnic nerve modulation in heart failure: mechanistic overview, initial clinical experience, and safety considerations
Splanchnic nerve modulation in heart failure: mechanistic overview, initial clinical experience, and safety considerations Open
Volume recruitment from the splanchnic compartment is an important physiological response to stressors such as physical activity and blood loss. In the setting of heart failure (HF), excess fluid redistribution from this compartment leads …
View article: Associations of Visceral, Subcutaneous, Epicardial, and Liver Fat with Metabolic Disorders up to 14 Years After Weight Loss Surgery
Associations of Visceral, Subcutaneous, Epicardial, and Liver Fat with Metabolic Disorders up to 14 Years After Weight Loss Surgery Open
Background: Bariatric surgery leads to long-term remission and reduced incidence of diabetes, hypertension, and dyslipidemia. Short-term studies suggest reduction in specific fat depots may be more predictive of health improv…
View article: Predictive Value of Cardiac CTA, Cardiac MRI, and Transthoracic Echocardiography for Cardioembolic Stroke Recurrence
Predictive Value of Cardiac CTA, Cardiac MRI, and Transthoracic Echocardiography for Cardioembolic Stroke Recurrence Open
BACKGROUND. Transthoracic echocardiography (TTE) is the standard of care for initial evaluation of patients with suspected cardioembolic stroke. Although TTE is useful for assessing certain sources of cardiac emboli, its diagnostic …
View article: Impact of Interatrial Shunts on Invasive Hemodynamics and Exercise Tolerance in Patients With Heart Failure
Impact of Interatrial Shunts on Invasive Hemodynamics and Exercise Tolerance in Patients With Heart Failure Open
Approximately 50% of patients with heart failure have preserved ejection fraction. Although a wide variety of conditions cause or contribute to heart failure with preserved ejection fraction, elevated left ventricular filling pressures, pa…
View article: Table of Contents
Table of Contents Open